Interpreting in-vitro data for sofosbuvir against SARS-CoV-2: cell lineage is key

Jacob Levi,1 Hannah Wentzel,2 Jonathan Falconer,3 Thiago Moreno L. Souza,4 Andrew Hill5

1.Department of Intensive Care Medicine, University College London Hospital, University College London, 235 Euston Road, London, NW1 2BU
2.School of Public Health, Imperial College London, St Mary’s Hospital, Norfolk Place, London, W2 1PG
3.Department of Molecular and Clinical Pharmacology, University of Liverpool, Ashton Street, Liverpool, UK, L69 3GE
4.Chelsea and Westminster NHS Foundation Trust, Chelsea and Westminster Hospital, Fulham Road, London, UK, SW10 9NH
5.Fiocruz, Rio de Janeiro, RJ, Brazil

Background
Various existing antimicrobials have been repurposed and tested to find an effective therapy for SARS-CoV-2, including sofosbuvir, which is known to have broad anti-viral effects against many viruses. Promising in-silico studies predicted strong binding for sofosbuvir with SARS-CoV-2 replication enzymes (RdRp). Whilst in-vitro studies showed mixed outcomes for sofosbuvir, small clinical trials showed potential benefits in combination with other antivirals. We summarise published in-vitro research on sofosbuvir efficacy when repurposed against SARS-CoV-2 and various other viruses.

Objectives and Methodology
We reviewed published in-vitro studies of sofosbuvir against SARS-CoV-2 and eight other viruses, to identify whether differences in cell lineage, viral strains and assay readout technique impacts IC50 results for sofosbuvir against various viruses.

Results
Data was available for published IC50 results for sofosbuvir across twelve different cell lines, for nine viruses; dengue, chikungunya, zika, yellow fever virus (YFV), west nile virus (WNV), SARS-CoV-2, and hepatitis A, C and E. We found cell lineage is a crucial factor when interpreting data from in-vitro trials of sofosbuvir, whilst other in-vitro lab methodology factors are also important, such as MOI, assay readout technique and viral isolate polymorphisms. Sofosbuvir seems inactive against all viruses in Vero E6 and A549 cells but is effective in other human cells, especially hepatocyte lineages such as HUH7 and HepG2 cells. This is also true for SARS-CoV-2. These findings are most likely because the commonly used Vero E6 and A549 cells lacks the key enzymes that are involved in the metabolism of sofosbuvir into its active form.

Conclusion
• The IC50 for a medication against a specific virus varies significantly depending on lab methodology, especially cell lineage.
• In order to effectively screen repurposed therapies as possible trial candidates for SARS-CoV-2, a pro-drug must be understood in the context of its intracellular metabolic activation pathway.
• We recommend human hepatocytes (HUH7, HepG2) or pneumocytes (Calu-3) rather than Vero E6 or A549 cells are used when researching sofosbuvir in SARS-CoV-2 and other viruses.

Sofosbuvir
As shown on the right, Sofosbuvir, is a Pro-Tide molecule requiring intracellular activation. Sofosbuvir is metabolized to its active triphosphate in a multistep pathway, starting with the removal of monophosphate protections by the enzymes CES1/CatA and HINT1. Next, sofosbuvir-monophosphate is converted to the active compound GS-461203. CES1/CatA and HINT1 are strongly expressed in human hepatocytes; hence sofosbuvir’s tropism for hepatic viruses, namely hepatitis C virus (HCV) for which it’s a licensed treatment. The CES1 enzyme is also expressed in alveolar epithelial cells, a cell type of interest in potential treatments for SARS-CoV-26 due to its damaging impact in the respiratory system.